Tarka and Retinal vessel occlusion - a phase IV clinical study of FDA data

Summary:

Retinal vessel occlusion is reported as a side effect among people who take Tarka (trandolapril; verapamil hydrochloride), especially for people who are male, 60+ old, also take Levitra, and have Osteopenia.

The phase IV clinical study analyzes which people have Retinal vessel occlusion when taking Tarka. It is created by eHealthMe based on reports of 2,361 people who have side effects when taking Tarka from the FDA, and is updated regularly.

What is Tarka?

Tarka has active ingredients of trandolapril; verapamil hydrochloride. It is often used in high blood pressure. eHealthMe is studying from 2,409 Tarka users. Check the latest studies of Tarka.

What is Retinal vessel occlusion?

Retinal vessel occlusion (a blockage in one of the small arteries) is found to be associated with 468 drugs and 831 conditions by eHealthMe. Check the latest studies of Retinal vessel occlusion.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Jul, 03, 2026

2,361 people reported to have side effects when taking Tarka.
Among them, 11 people (0.47%) have Retinal vessel occlusion.

Could Tarka cause Retinal vessel occlusion?

Among these 11 people:

What is the gender of people who have Retinal vessel occlusion when taking Tarka? *

female: 9.09 %
male: 90.91 %

What is the age of people who have Retinal vessel occlusion when taking Tarka? *

What are other drugs people take besides Tarka? *

What are other side effects people have besides Retinal vessel occlusion? *

Amaurosis Fugax (painless transient monocular visual loss): 6 people, 54.55%
Headache (pain in head): 5 people, 45.45%
Blindness Unilateral: 5 people, 45.45%
Dizziness: 5 people, 45.45%
Amblyopia (lazy eye): 2 people, 18.18%
Arterial Thrombosis (formation of a blood clot inside a blood vessel, obstructing the flow of blood through the circulatory system): 1 person, 9.09%
Dyspnea (difficult or laboured breathing): 1 person, 9.09%
Gastric Disorder (disease of stomach): 1 person, 9.09%
Visual Field Defect: 1 person, 9.09%
Visual Disturbance: 1 person, 9.09%

What are the existing conditions these people have? *

Osteopenia (a condition where bone mineral density is lower than normal): 1 person, 9.09%

* Approximation only. Some reports may have incomplete information.

Do you take Tarka and have Retinal vessel occlusion?

- Check whether Retinal vessel occlusion is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Tarka:

Tarka (2,409 reports)

Retinal vessel occlusion treatments and more:

Retinal vessel occlusion (10,555 reports)

How severe was Retinal vessel occlusion and when was it recovered:

Retinal vessel occlusion in Tarka

Expand to all the drugs that have ingredients of trandolapril; verapamil hydrochloride:

Retinal vessel occlusion and drugs with ingredients of trandolapril; verapamil hydrochloride (11 reports)

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Tarka:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Retinal vessel occlusion:

Retinal vessel occlusion (468 drugs)

Browse all the conditions that are associated with Retinal vessel occlusion:

Retinal vessel occlusion (831 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on trandolapril; verapamil hydrochloride (the active ingredients of Tarka) and Tarka (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.